A Multi-Institutional Study of the Impact of the COVID-19 Pandemic on Diagnosis and Pharmacotherapy of Diabetic Macular Edema

A Multi-Institutional Study of the Impact of the COVID-19 Pandemic on Diagnosis and Pharmacotherapy of Diabetic Macular Edema - A Multi-Institutional Study of the Impact of the COVID-19 Pandemic on Diagnosis and Pharmacotherapy of Diabetic Macular Edema

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048935

Enrollment

20000

Registered

2022-09-14

Start date

2022-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received intravitreal injections of aflibercept, ranibizumab, or triamcinolone acetonide for diabetic macular edema at the study institution between January 1, 2019, and March 18, 2022

Exclusion criteria

Exclusion criteria: Patients who refused to enroll in this study or who were participating in other clinical trials

Design outcomes

Primary

Measure	Time frame
Association between the number of intravitreal injections of anti-VEGF drugs for diabetic macular edema after a COVID-19 outbreak (January 1, 2020 to March 18, 2022) and the number of new COVID-19 infections.	—

Countries

Japan

Contacts

Public ContactRyohei Komori

University of Fukui Hospital ophthalmology

fganka@med.u-fukui.ac.jp0776-61-8403

Outcome results